>Forum on UK Pharmacovigilance post-Brexit

  • Venue: Royal College of Physicians, London
  • Date: 26 Apr 2017
  • Cost per delegate:
    • Or £300 + VAT registration-fee

      (excluding VAT, total including VAT £360.00)

Book your place

Clear

Introduction

Vector illustration, eps 10.

What will the role of UK Pharmacovigilance (PV) be after the UK leaves the EU?

The UK currently plays a major role in European PV, with MHRA assessing more drug applications for the EMA than any other national competent authority and with the UK hosting many pharma companies, QPPVs and PV experts. There is an enthusiasm to maintain much of the status quo of UK PV in relation to EU PV, but the degree to which may be possible post-Brexit is not clear. There are several possible models.

UK PV is enriched by expertise and resources from all over the EU and likewise these EU citizens are gaining experience from working in the UK, a key PV powerhouse.  Continued integration of UK PV with European PV has benefits for patients and public health both in the UK and the EU. It also facilitates the development and maintenance of effective and safe medicines.

Join us to hear the latest from a panel of experts and help us set the scene of Pharmacovigilance in the UK in relation to Europe after the UK leaves the EU.

Confirmed speakers include:

  • Virginia Acha, The Association of the British Pharmaceutical Industry
  • Vicki Edwards, Abbvie
  • Thomas Lönngren, NDA Group
  • Lincoln Tsang, Arnold & Porter Kaye Scholer LLP
  • John Warren, Medicines Assessment Ltd
  • Saad Shakir, DSRU